SPRING - Assess the Clinical Care Pathway of Population With T2D and CKD in Four European Countries Using Real-world Data
NCT ID: NCT06769646
Last Updated: 2025-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110074 participants
OBSERVATIONAL
2024-12-02
2025-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective is to describe the population with T2D and CKD in terms of demography, clinical characteristics and medication use by CKD stage.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Diabetic Patients With End-Stage Renal Disease
NCT00435786
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
NCT01069926
Mechanisms Underlying SGLT2i Kidney Effect in DKD Progression
NCT07270198
Reducing Risk of Diabetic Ketoacidosis in Type 1 Diabetes and Kidney Disease Using Continuous Ketone Monitoring
NCT07325201
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People with T2D in THIN databases
Individuals from the THIN® France, THIN® Italy, THIN® Spain and THIN® UK databases living with T2D and CKD
No tretament given
No treatment given
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No tretament given
No treatment given
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. With evidence of Kidney damage before or at index date:
1. diagnosed with CKD
2. or with a record of eGFR below 60 ml/min/1.73 m\^2
3. or with a record of uACR above 30 mg/g
3. Consulting a GP (all countries) or an Endocrinologist (France, Spain, Italy) or a Nephrologist (Spain) of the THIN® network.
Exclusion Criteria
2. less than 360 days prior index date
3. less than 360 days after index date
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Transparency (dept. 2834)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational site
Bangalore, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
U1111-1313-1011
Identifier Type: OTHER
Identifier Source: secondary_id
DAS-8385
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.